Singla, Nirmish <br/><br/>
Re: Brian I. Rini, Thomas Powles, Michael B. Atkins, et al. Atezolizumab plus Bevacizumab Versus Sunitinib in Patients with Previously Untreated Metastatic Renal Cell Carcinoma (IMmotion151): A Multicentre, Open-label, Phase 3, Randomised Controlled Trial. Lancet 2019;393:2404-15: Putting IMmotion into Motion: Personalizing Frontline Treatment for Metastatic Renal Cell Carcinoma.  [electronic resource] 

 -  European urology  06 2020 
 - e168-e169 p.  digital 
<br/><br/> Publication Type: Letter; Comment 
<br/><br/><label>ISSN: </label>1873-7560 
<br/><br/><label>Standard No.: </label>10.1016/j.eururo.2019.09.015  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal, Humanized<br/>Bevacizumab<br/>Carcinoma, Renal Cell--drug therapy<br/>Humans<br/>Kidney Neoplasms--drug therapy<br/>Sunitinib